论文部分内容阅读
随着对类风湿性关节炎(RA)病理研究的不断深入,治疗新药不断问世。其中包括晚近开发的3种缓解病情抗风湿药(DMARDs)和2种选择性环氧合酶-2(COX-2)抑制剂。上述新药适用于各年龄段的RA。本文就其近况作一简介。 RA的早期干预及目的.晚近认为,治疗RA应尽可能达到下述4项目的:控制病情活跃、缓解疼痛、维系功能和减缓关节损害。为此美国风湿病学会最近建议,对于所有早期RA者,一经确诊均应在3个月内接受DMARDs,直至急性期症状体征完全缓解。以下分述该5种新药。
With the deepening of the pathology of rheumatoid arthritis (RA), the treatment of new drugs continue to come out. These include the recently developed 3 disease-modifying antirheumatic drugs (DMARDs) and 2 selective cyclooxygenase-2 (COX-2) inhibitors. The new drug is suitable for all ages RA. This article gives a brief introduction of its current situation. RA early intervention and purpose.Recently, the treatment of RA should be as much as possible to achieve the following four items: control of active disease, relieve pain, maintain function and reduce joint damage. To this end the American College of Rheumatology recently recommended that for all patients with early RA, once diagnosed should receive DMARDs within 3 months, until the acute symptoms and signs of complete remission. The following describes the five new drugs.